LIMN
Liminatus Pharma, Inc.
Healthcare — Biotechnology
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
None
$3.79
+$0.06 (+1.61%)
Price History
52-Week Range
Sign in to add LIMN to a watchlist or set price alerts.
Fundamentals
| Market Cap | $5.81M |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-0.25 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 33.8 |
| Beta | 0.70 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $10.20 |
| 52-Week Low | $0.10 |
| 50-Day Avg | $0.17 |
| 200-Day Avg | $0.66 |
| Avg Volume | $11.86M |
| Volume | $22.83M |
Performance Analysis
NEUTRALLIMN presents a mixed picture with both positive and negative indicators.
~
Trading at 37% of its 52-week range.
~
RSI at 33.8 is in neutral territory.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Jul 02, 2026 13:18 UTC
Back to Screener Export Report